Register for our free email digests:
Latest From Alpharma LLC
The firm is reducing its non-production workforce by 750, a decision made after three representatives of disgruntled investor Starboard Value joined its board. Perrigo charts a course of recovery for its struggling international consumer health business, but some analysts are convinced it took a wrong turn with its 2015 investment in European OTC drug and nutritional product businesses and brands.
3i sells Nordic antibacterial manufacturer Xellia Pharmaceuticals, which has plans to develop novel antibiotics, new formulations and new bulk generics.
Watson’s merger with Actavis will create the world’s third-largest generic drug company, to be known as Actavis, with significant ex-U.S. market share, especially in the U.K., Nordic countries and Russia.
With the Actavis deal finalized, Watson achieves its long-sought goal of becoming a major international player in generics, and announces a new global management team to undertake the critical component: execution.
- Therapeutic Areas
- Western Europe
- Parent & Subsidiaries
- Naturex SA
- Senior Management
Thierry Lambert, CEO
Marc Roller, Scientific Dir.
- Contact Info
Phone: 4 90 23 96 89
Site d'Agroparc - BP 1218
You must sign in to use this functionality
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.